MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia

Int J Hematol. 2003 Dec;78(5):439-42. doi: 10.1007/BF02983817.

Abstract

We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia. Our case is of interest because of simultaneous relapse of the original leukemia and onset of therapy-related leukemia and relatively rare t(1;11)(p32;q23) translocation with confirmed MLL/AF-1p fusion. This case suggests that careful monitoring for MLL gene rearrangements is necessary after administration of topoisomerase II inhibitors.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chromosomes, Human, Pair 1 / genetics*
  • Chromosomes, Human, Pair 1 / ultrastructure
  • Chromosomes, Human, Pair 11 / genetics*
  • Chromosomes, Human, Pair 11 / ultrastructure
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects*
  • Etoposide / administration & dosage
  • Etoposide / adverse effects*
  • Fatal Outcome
  • Humans
  • Idarubicin / administration & dosage
  • In Situ Hybridization, Fluorescence
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Male
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Myeloid-Lymphoid Leukemia Protein
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasms, Second Primary / chemically induced
  • Neoplasms, Second Primary / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / chemically induced
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Recurrence
  • Topoisomerase II Inhibitors
  • Translocation, Genetic*
  • Tretinoin / administration & dosage

Substances

  • Antineoplastic Agents, Phytogenic
  • Enzyme Inhibitors
  • MLL-AF-1p fusion protein, human
  • Neoplasm Proteins
  • Oncogene Proteins, Fusion
  • Topoisomerase II Inhibitors
  • Cytarabine
  • Myeloid-Lymphoid Leukemia Protein
  • Tretinoin
  • Etoposide
  • Mitoxantrone
  • Idarubicin
  • Daunorubicin